Member access

4-Traders Homepage  >  Shares  >  Euronext Alternext  >  MEDIAN TECHNO    ALMDT   FR0011049824

MEDIAN TECHNO (ALMDT)

6
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

MEDIANTECHNOLOGIES : MEDIAN Technologies Joins Forces with Quintiles to Provide World-Class Clinical Trial Imaging Services

02/16/2012 | 12:35pm US/Eastern

Regulatory News:

Strategic agreement to leverage MEDIAN's advanced lesion management system (LMS) software applications and associated clinical trial imaging services for early, late-stage or post-approval oncology clinical trials

To improve the assessment of how cancer patients are responding to investigational therapies in clinical trials, MEDIAN Technologies (Paris:ALMDT) today announced a strategic agreement with Quintiles to offer advanced integrated image services to biopharmaceutical customers worldwide.

The agreement with Median, a leading services provider for image interpretation and management in oncology clinical trials, is designed to further strengthen Quintiles' full range of services to accelerate oncology drug development. With Quintiles, the world's leading biopharmaceutical services provider, as its partner, Median can extend the reach of its technologies in the clinical development field to benefit customers globally.

"This collaboration will result in better quality of data, increased awareness for biopharma for go/no-go decisions along the drug development stages, and ultimately more robust regulatory submission to health agencies," said MEDIAN Chief Executive Officer Fredrik Brag.

Under terms of the agreement, Quintiles will have the potential to be awarded warrants, which if exercised could amount to up to a 15% equity position in the company.

Anne Pilling, Vice President, Quintiles Oncology Therapeutic Delivery Unit, said: "This partnership complements Quintiles' current portfolio of imaging solutions and provides further proof of our commitment to provide biopharma and healthcare service providers with the tools, expertise and services needed to increase productivity and better the lives of patients."

Images are essential in clinical trials and are used at all steps of cancer care, from patient diagnosis to monitoring. In clinical trials, they provide a critical indication of patient response to treatment of new candidate drug and are used as input for new drug and therapeutic schemes registration. MEDIAN's solution addresses two critical imaging challenges: data variability amongst readers and efficient management of the imaging data workflow.

About Quintiles: Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com

About MEDIAN Technologies: Based in Sophia Antipolis, MEDIAN was founded in 2002 by Fredrik Brag (Current CEO), Gérard Milhiet and Arnaud Butzbach. The company has a staff of 40, over half of whom work in R&D, and has a subsidiary in the USA.

MEDIAN Technologies offers solutions and services for diagnosing and monitoring cancer patients for clinical trials market in oncology, its priority market, and the patient care market. MEDIAN a collaborated with institutes at the cutting edge of medical imaging, among which the French National Institute for Computer Science and Control (INRIA), Chicago University and the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL).

MEDIAN Technologies has been present in the market since 2007 through direct and indirect sales of its LMS solutions and alliances with specialist cancer centers in Europe and the USA.

For more information on MEDIAN, please visit: www.mediantechnologies.com

QUINTILES
Quintiles Media Relations
Jay Johnson
+1 919 993 2066
jay.johnson@quintiles.com
or
Quintiles Investor Relations
Greg Connors
+1 919 998 2000
invest@quintiles.com
or
MEDIAN
MEDIAN Technologies
Fredrik Brag, CEO
+33 492 906 582
fredrik.brag@mediantechnologies.com
or
Press
ALIZE RP
Caroline Carmagnol
+ 33 664 189 959
+ 33 142 688 643
caroline@alizerp.com
Anne-Sophie Cosquéric
+ 33 1 42 68 86 41
anne-sophie@alizerp.com
or
Investors
ACTIFIN
Anaïs de Scitivaux
+ 33 1 56 88 11 14
adescitivaux@actifin.fr


© Business Wire 2012
Latest news on MEDIAN TECHNO
10/09 MEDIAN TECHNO : ogies : 2014 First Half Results in Line with Expectations
10/08 MEDIAN TECHNO : Steps up Its Development: New Project Awards and a New Contract ..
10/06 MEDIAN TECHNO : ogies : Approval of the Reserved Capital Increase of €20 Million
09/24 MEDIAN TECHNO : ogies : to Present Study Results at the ESMO 2014 Congress in Ma..
08/25 MEDIAN TECHNO : ogies : Announces a Reserved Capital Increase of €20 Million
08/25 MEDIAN TECHNO : ogies : Announces a Reserved Capital Increase of €20 Million
06/19 MEDIAN TECHNO : ogies : is Laureate of FACCNE’s 13th Annual Business Award..
05/28 MEDIAN TECHNO : ogies : To Participate in the 2014 ASCO Annual Conference
04/08 MEDIAN TECHNO : ogies : Announces €422K Phase II Project Award
03/22 MEDIAN TECHNO : ogies Enters into EUR700K Pact with a Top 5 Pharmaceutical Compa..
Advertisement
Chart
Duration : Period :
MEDIAN TECHNO Technical Analysis Chart | ALMDT | FR0011049824 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF